How can an epilepsy drug prevent Alzheimer’s?

A different way to tackle early Alzheimer’s changes

New research shows that an existing, FDA‑approved anticonvulsant operates on the upstream chemistry that produces toxic amyloid peptides, rather than removing plaques once they have accumulated. Laboratory studies indicate the drug reduces the generation of those small, harmful peptides at an early stage — potentially slowing the cascade that leads to plaque formation, inflammation and neuronal loss.

This mechanistic shift matters because most current Alzheimer’s therapies focus on clearing amyloid plaques after they form. A compound that curbs the initial production of toxic fragments would be a preventive strategy: given before widespread plaque accumulation, it might delay or prevent the disease process from gaining traction.

Implications for patients and research

• Repurposing an approved seizure medication could accelerate clinical testing because safety data already exist for its licensed indications.
• Trials will need to test whether the biochemical effects translate into meaningful delays in cognitive decline in people at risk, and to define the optimal timing and dose.
• Researchers must assess long‑term safety in older adults and potential interactions with other medications commonly taken in later life.

What still needs to be shown

Early results are promising, but they come from preclinical or early‑stage studies; large, well‑controlled clinical trials are required to demonstrate that the biochemical effect prevents dementia or slows its progression. It is also unclear which populations would benefit most — for example, people with genetic risk factors or those with early biomarker changes — and whether a preventive approach would be broadly practical and cost‑effective.